Grifols Joins the SpCCJ

We are delighted to welcome Grifols, a global healthcare company founded in Barcelona, Spain, in 1909, as a new Corporate Member.

Grifols is a worldwide leader in plasma-derived medicines and transfusion medicine, developing, producing, and delivering innovative healthcare solutions in more than 110 countries. With a legacy spanning over a century, the company’s mission remains centered on improving the health and well-being of people around the world through continuous innovation driven by patient needs.

The company focuses on four key therapeutic areas: immunology, infectious diseases, pulmonology, and critical care. As a pioneer in plasma science, Grifols operates the world’s largest network of plasma donation centers, with nearly 400 centers across North America, Europe, Africa, the Middle East, and China. Through its vertically integrated model and its unwavering commitment to quality and safety, Grifols continues to set the global benchmark in plasma-derived therapies and transfusion medicine.

Beyond plasma-derived medicines, Grifols provides clinical diagnostic technologies, biological materials for research, and a range of professional tools and services that empower healthcare providers to deliver expert medical care more efficiently. With over 23,800 employees in more than 30 countries and regions, Grifols stands as a trusted partner in advancing global health.

Grifols’ relationship with Japan spans more than four decades, dating back to the 1970s when the company began exporting its products to the country. Since establishing a direct presence in Japan in 2006, Grifols has strengthened its collaboration with key healthcare partners to bring innovative diagnostic and plasma-derived solutions to Japanese patients.

We are proud to count Grifols among our members and look forward to fostering new opportunities for collaboration between Grifols, Japan, and the broader Spanish business community.